Bayer Gains US Approval for Sunharbo, Stock Rises

Bayer’s stock price rose 1.5% Tuesday following US Food and Drug Administration (FDA) approval of Sunharbo (asundexian), a successor drug to the blockbuster Xarelto for stroke prevention, signaling renewed momentum in the company’s pharmaceutical pipeline. The approval, which covers use in patients experiencing non-cardioembolic ischemic strokes, provides a critical growth driver as Xarelto faces increasing competition from generic alternatives.

Analysts at Jefferies noted the FDA approval significantly lowers risk within Bayer’s pharmaceutical development program, though they caution that Sunharbo will only address approximately 40% of all stroke cases. While initial market expectations position Sunharbo as a potential blockbuster with estimated peak sales of around €5 billion, Jefferies estimates a more conservative addressable market of €2 billion due to its limited application. This tempered outlook reflects the complexities of market penetration even with a novel drug in a significant market.

The positive news builds on recent gains for Bayer, as the stock has increased by more than 50% year-to-date, largely driven by favorable outcomes in glyphosate lawsuits. The FDA decision alleviates concerns over Bayer’s ability to offset revenue declines from both Xarelto and Eylea, two key products facing patent expirations and generic competition. The approval, however, comes as German Health Minister Carsten Linnemann signals a reluctance to offer pricing advantages to pharmaceutical companies investing in German production without impacting statutory health insurance contributions, potentially creating future cost pressures.

The FDA approval of Sunharbo marks a crucial step in Bayer’s strategy to revitalize its pharmaceutical portfolio, offering a new avenue for growth in a competitive market. However, the drug's limited scope and potential pricing headwinds in Germany pose ongoing challenges to realizing its full potential.